Lonza, global supplier to the pharmaceutical, biotech and specialty ingredients markets, has been granted a US patent for the use of L-Carnitine in petfood owing to its beneficial impact on performance and recovery in active dogs. The product, Carniking L-Carnitine, is approved for use in dog food, wet and dry treats, and complete feeds, base mixes or premixes.
Carniking helps maintain lean muscle mass by reducing muscle degradation and oxidative stress which results from intense physical activity and may improve the quality of life of active dogs, service dogs and tracking dogs. L-Carnitine also helps animals, similarly to humans, utilise dietary fat in producing energy.
Carniking utilises dietary fat for energy by moving long- and medium-chain fatty acids across the outer and inner-mitochondrial membrane so they can be metabolised and converted into energy.
Four canine research studies were conducted by Lonza, during which Carniking was shown to improve exercise performance and activity, as well as lean mass, muscle recovery and oxidative stress during exercise.
“Bringing together 30 years of investment and discovery in L-Carnitine, Lonza’s new patent for L-Carnitine as Carniking highlights our continued commitment to exploring its health benefits for both animals and humans,” noted Kevin Owen, Ph.D., head of global business development for Lonza companion animal division and co-owner of the patent. “Backed by robust science, the patent confirms that L-Carnitine is good for both you and for your dog.”
For more information visit Lonza’s website, HERE.
